Might 7, 2026 – Medline Inc. reported its working outcomes for the three months ended March 28, 2026.

First Quarter 2026 Outcomes

Internet gross sales within the first quarter of 2026 elevated 10.7% to $7.4 billion, in comparison with $6.6 billion within the first quarter of 2025, with natural gross sales growing 10.1%. This was primarily pushed by the implementation of latest prospects from 2025 and the expansion of current prospects.

Internet revenue within the first quarter of 2026 decreased 25.8% to $239 million, in comparison with $322 million within the first quarter of 2025, primarily because of greater price of products offered, together with the influence of tariffs, greater working bills to assist new buyer development and an worker bonus associated to the corporate’s preliminary public providing. This was partly offset by greater internet turnover and decrease curiosity costs.

Adjusted EBITDA within the first quarter of 2026 decreased 10.6% to $776 million, in comparison with $868 million within the first quarter of 2025, primarily because of greater price of products offered, together with the influence of tariffs, and better working bills to assist new buyer development, partially offset by greater internet gross sales.

Diluted earnings per share and adjusted diluted earnings per share had been $0.16 and $0.33, respectively.

Internet money from working actions within the first quarter of 2026 was $412 million, pushed by internet revenue, excluding the influence of non-cash gadgets, partially offset by adjustments in working capital primarily because of elevated commerce receivables associated to gross sales development and elevated inventories.

Free money movement within the first quarter of 2026 was $316 million, pushed by internet money from working actions, partially offset by capital expenditures primarily associated to continued enhancements and automation on the firm’s distribution facilities and investments in its kitting manufacturing amenities.

2026 Steerage
The corporate raises its full-year 2026 natural gross sales development outlook to eight.5% to 9.5%, up from earlier steerage of 8% to 9%, and maintains its Adjusted EBITDA steerage of $3.5 to $3.6 billion.

Proceed studying